

Technology Advisory Committee C Interests Register

Topic [ID6290]

Publication Date: 15/05/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Steven Lloyd	TAC C Committee Member	Direct- financial	Dr Steven Lloyd worked with Viatrix UK in advisory capacity within last 12 months on influenza vaccines programmes.	01/03/2023	It was agreed that Dr Steven Lloyd's declaration would not prevent him from participating in discussions on this appraisal
Stella O'Brien	TAC C Committee Member	Non-financial professional interests	Stella O'Brien is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK's research and academic communities. Although CAR-T therapies are an example of ATMPs, Stella O'Brien has not contributed to	16/02/2024	It was agreed that Stella O'Brien's declaration would not prevent her from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>work on CAR-T therapies with this group.</p> <p>Stella O'Brien is a public member of the expert panel for the NIHR Research Call for the Optimisation of Cellular Therapies (improving patient care with the establishment of a CAR-T manufacturing facility in the UK and improving the resilience and efficiency of supply chains). It's to facilitate NHS access to scalable, affordable and state-of-the-art CAR-T cell manufacturing capability and ultimately improve patient access to CAR-T and other advanced cellular therapies and in addition to their outcomes. Standard Involve rate honoraria apply.</p>		
Satish Venkateshan	TAC C Committee Member	Direct- financial	Regeneron is developing therapeutics for a broad range of diseases including B-cell and other haematologic malignancies. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish Venkateshan also owns	19/02/2024	It was agreed that Satish Venkateshan's declaration would not prevent him from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			shares in the company and has stock options		
Michael Chambers	TAC C Committee Member	Direct- financial	Michael Chambers is a member of an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has have provided consulting advice to Sanofi in an unrelated disease area (COPD)	19/02/2024	It was agreed that Michael Chambers's declaration would not prevent him from participating in discussions on this appraisal
Dr Richard Nicholas	TAC C Committee Member	Direct- financial	Dr Richard Nicholas has attended advisory boards by Novartis in an unrelated disease area - multiple sclerosis.	03/03/2024	It was agreed that Dr Richard Nicholas' declaration would not prevent him from participating in discussions on this appraisal
Dr Kate Ren	TAC C Committee Member	Direct- financial	Dr Kate Ren provided internal peer review of the EAG report for TA ID6290 on the MAIC section. Dr Ren also provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	19/02/2024	It was agreed that Dr Kate Ren's declaration would prevent her from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Dr Kate Ren was conflicted and did not attend this discussion.		
Dr Sara Ghorashian	Clinical expert	Direct- financial Indirect- financial	Dr Sara Ghorashian has received payment to provide clinical validation of assumptions in the Novartis economic model to inform the company submission to NICE for this appraisal. Through Dr Ghorashian's development of AUTO1, a novel cd19 CAR T cell therapy, Dr Ghorashian is inventor on the UCLB patent which has been licensed to Autolus Ltd and may receive future royalties. Dr Ghorashian's husband owns shares in Autolus and Amgen	17/08/2023	It was agreed that Dr Sara Ghorashian's declaration would not prevent her from providing expert advice to the committee.
Sophie Wheldon	Patient expert	Non-financial professional interests	Sophie Wheldon works for her nominating organisation, Leukaemia Care.	23/08/2023	It was agreed that Sophie Wheldon's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
		Indirect- financial	Leukaemia Care has received funding from Amgen for support services, core funding from Incyte and Pfizer, and core funding and honorarium from Novartis.		